Výsledky vyhledávání - "David Bharucha"

Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program

Autor: Paurus Irani, Karen Cheng, Margaret Tawadrous, Joseph W. Chow, Yehuda Carmeli, John E. Mazuski, Antoni Torres, Florian M.E. Wagenlehner, David Bharucha, Gregory G. Stone, Dalia B. Wajsbrot

Publikováno v: Infectious Diseases and Therapy

Introduction This exploratory analysis assessed efficacy and safety outcomes in patients with Gram-negative bacteremia treated with ceftazidime-avibactam or comparator across five phase 3, randomized, controlled, multi-center trials in adults with co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::331d39299797ea92851493063335f89d
https://pubmed.ncbi.nlm.nih.gov/34374952

Zobrazit plný text záznamu

Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF

Autor: David G. Soergel, Piotr Ponikowski, Gerasimos Filippatos, Javed Butler, Sean P. Collins, Phillip D. Levy, Kathleen Goin, Adriaan A. Voors, G. Michael Felker, Gad Cotter, Stefanie Senger, Beth A. Davison, John R. Teerlink, Peter S. Pang, Justin A. Ezekowitz, David Bharucha, Marco Metra

Publikováno v: Clinical Research in Cardiology, 107(2), 170-181. SPRINGER HEIDELBERG

Introduction TRV027, a 'biased' ligand of the angiotensin II type 1 receptor (AT1R), did not affect a composite clinical outcome at 30 days in a phase 2b acute heart failure (AHF) trial (BLAST-AHF).Methods Post-hoc analyses from BLAST-AHF (n = 618) e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45b1ea4f5d216db0276646f6167a7733
https://doi.org/10.1007/s00392-017-1168-0

Zobrazit plný text záznamu

Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure

Autor: Kathleen Goin, Gerasimos Filippatos, David G. Soergel, Sean P. Collins, Phillip D. Levy, David Bharucha, Gad Cotter, Beth A. Davison, Piotr Ponikowski, John R. Teerlink, Marco Metra, Peter S. Pang, Javed Butler, Adriaan A. Voors, G. Michael Felker, Justin A. Ezekowitz

Publikováno v: European heart journal, vol 38, iss 30
European Heart Journal, 38(30), 2364-2373. Oxford University Press

Aims: Currently, no acute heart failure (AHF) therapy definitively improves outcomes. Reducing morbidity and mortality from acute heart failure (AHF) remains an unmet need. TRV027 is a novel ` biased' ligand of the angiotensin II type 1 receptor (AT1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8a05e9fbea281bc24f53cf6b5459aa2
https://doi.org/10.1093/eurheartj/ehx196

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání